Cagrilintide-semaglutide reduces HbA1c by up to 2.33% in adults with type 2 diabetes
New insulin combination shows promise for managing type 2 diabetes
This Phase 3a randomized controlled trial of 274 adults with type 2 diabetes found that adding cagrilintide-semaglutide to basal insulin sig…
A new drug combination added to daily insulin helps lower blood sugar and body weight in adults with type 2 diabetes.
Cagrisema produces greater weight loss than semaglutide in obesity meta-analysis
New analysis shows cagrisema beats semaglutide for weight loss in obesity
This systematic review and meta-analysis of 3,545 individuals with obesity found that cagrisema produced significantly greater weight loss t…
A large meta-analysis found cagrisema produced greater weight loss than semaglutide, while cagrilintide alone matched semaglutide results in…
CagriSema demonstrates superior weight loss efficacy compared to semaglutide monotherapy or placebo in obesity trials
New drug combo beats standard treatment for obesity and heart risks
A systematic review and meta-analysis of 4,419 patients reveals CagriSema drives greater weight loss than semaglutide alone. However, clinic…
This new drug combination helps people lose more weight and lowers blood pressure, but it causes more stomach upset that needs careful watch…